|
- Brand：Knowlux
- Model：Bottle/Drum/Customized to your needs
- Purity：99%
- Cas：2259884-03-0
- Createtime： 2026-11-03
- Updatetime： 2026-11-03
| useage | Laboratory research，Food/nutraceutical industry (regulated forms only)，Cosmetics |
| deliveryInfo | |
| sample availble | Yes |
| appearance | Yellow to light yellow viscous liquid or oil |
| aliasen | |
| supplyCapacity | 10/ |
| harbor | |
| minorder | 2 |
| Molecular Formula: | C210H322N46O67 |
Mazdutide (IBI362) | CAS 2259884-03-0 | Dual GLP-1/GCGR Receptor Agonist (Research Use Only) | Knowlux
Product Description
Mazdutide, CAS 2259884-03-0, is a synthetic dual glucagon-like peptide-1 (GLP-1) and glucagon receptor (GCGR) agonist supplied by Knowlux for laboratory research use. It is a long-acting peptide incorporating a fatty acyl side chain that extends its duration of action to support once-weekly dosing. The molecular formula is C210H322N46O67 and the molecular weight is 4563.07 g/mol. Each lot is released with a lot-specific COA, MSDS and full analytical traceability.
Product Parameters
| Item | Specification |
|---|---|
| Product Name | Mazdutide |
| Synonyms | IBI362; LY3305677; IBI-362 |
| CAS No. | 2259884-03-0 |
| Molecular Formula | C210H322N46O67 |
| Molecular Weight | 4563.07 g/mol |
| Sequence Length | Long-acting synthetic peptide with fatty acyl side chain |
| Key Structural Features | Fatty acyl side chain for extended half-life; dual GLP-1R/GCGR agonist |
| Appearance | White to off-white lyophilized powder |
| Purity | >=98.0% (HPLC); >=99.0% available on request |
| Identity | Confirmed by LC-MS and peptide mapping |
| Grade | Research grade |
| Counter-ion | Acetate or TFA (lot-specific, declared on COA) |
| Moisture | <=8.0% (Karl Fischer) |
| Storage | -20 C, protected from light and moisture; reconstituted solution 2-8 C, use within 7 days |
| HS Code | 2937.19.00 |
| Packaging | 1 mg / 5 mg / 10 mg / 50 mg / 100 mg vial; bulk on request |
| MOQ | 10 mg (research grade); 100 mg (bulk) |
| Supply Ability | Milligram to gram scale |
| Application | Laboratory research use only |
| Origin | China |
Product Details
1. Overview
Mazdutide (IBI362) is a dual agonist targeting the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). It was developed for the treatment of obesity and type 2 diabetes, and received approval in China in June 2025 for long-term weight management, followed by approval for glycaemic control in September 2025. The molecule incorporates a fatty acyl side chain that enables albumin binding and once-weekly subcutaneous administration. Clinical trials in Chinese populations have reported substantial weight reductions, with the GLORY-2 Phase III trial showing a mean weight reduction of 18.55% at 60 weeks with the 9 mg dose.
2. Mechanism of Action
Mazdutide activates both GLP-1 and glucagon receptors, combining the appetite-suppressing and glucose-lowering effects of GLP-1R agonism with the energy-expenditure-promoting effects of GCGR activation. Preclinical studies indicate that dual GLP-1R/GCGR activation reprograms hepatic lipid metabolism by suppressing lipid uptake, de novo lipogenesis, and lipid droplet formation, primarily through modulation of PPAR signalling pathways. At one-third the dose of semaglutide, mazdutide achieved comparable glucose-lowering effects and more pronounced weight loss in diet-induced obese mouse models. The glucagon receptor component is associated with a cardio-stimulant effect that may increase heart rate relative to selective GLP-1 receptor agonists.
3. Quality Control
| Test Item | Method |
|---|---|
| Purity | RP-HPLC |
| Identity & molecular mass | LC-MS (deconvoluted) |
| Primary structure | Peptide mapping / amino acid analysis |
| Counter-ion content | Ion chromatography (acetate or TFA) |
| Moisture | Karl Fischer |
| Appearance | Visual |
| Related substances | RP-HPLC |
| Microbial limits | Membrane filtration (on request) |
4. Applications
-
Reference standard and impurity studies for dual GLP-1/GCGR agonist analytical methods
-
GLP-1R and GCGR binding and functional assay development
-
Formulation development for long-acting injectable peptides
-
Metabolic disease model research, including obesity, glucose homeostasis and hepatic lipid metabolism studies
-
LC-MS, immunoassay and bioassay calibrators
5. Packaging, Storage & Shipping
Lyophilized powder: amber glass vial under nitrogen headspace, sealed with butyl stopper and aluminium crimp. Secondary packing: tamper-evident, light-protected carton with desiccant. Cold-chain shipping with validated gel packs and temperature logger; dry ice for -20 C shipments. COA, MSDS, packing list and certificate of origin issued with each shipment.
6. Documentation Support
Per lot: COA, MSDS, certificate of origin, residual solvent statement, counter-ion specification. Regulatory packages (specification summaries, audit support) available on a project basis.
About Knowlux
Knowlux Biotechnology is a GMP-oriented manufacturer and supplier of peptides, APIs and fine-chemical research compounds, operating from Hubei, China. We serve research groups, CDMOs and distributors in more than 40 countries, and support contract synthesis, custom packaging and technical documentation requests.
Compliance Statement
This product is supplied for laboratory research use only. It is not for human or animal administration, not for diagnostic or therapeutic use, not for retail sale, and not for personal use. Mazdutide received approval in China in 2025 for weight management and glycaemic control; that regulatory status is specific to the approved pharmaceutical product and does not extend to this research-grade supply as sold by Knowlux. In the United States and European Union, mazdutide is not approved as a therapeutic agent. Research context statements are for scientific reference only and do not constitute medical advice, promotional claims, or dosing guidance.
